BBInternational s gold nanoparticles have been selected by the National Institute of Standards and Technology (NIST) as the source for a series of certified reference materials for pre-clinical biomedical research.
Veeco Instruments Inc., a leading provider of instrumentation to the nanoscience community, announced today that the M.E. Mueller Institute for Structural Biology at the Biozentrum in Basel, Switzerland, has selected its BioScope II Atomic Force Microscope to aid in its cutting edge life sciences research program.
T2 Biosystems, Inc., a company developing the first portable medical diagnostic products which combine nanotechnology and miniaturized magnetic resonance imaging (MRI) technology, today announced the appointment of John McDonough as Chief Executive Officer.
Braggone, the optoelectronics materials company, has received multi-million dollar funding from TEKES (The National Technology Agency of Finland) to commercialize their polymer materials for worldwide commercialization.
Mazda Motor Corporation has developed a world's first catalyst for cars that uses nanotechnology to create a catalyst material structure which substantially reduces the amount of precious metals that are used, such as platinum and palladium.
Altair Nanotechnologies, Inc., a leading manufacturer of safe, high-performance lithium-titanate battery and energy storage products announced today that it completed on schedule in December the manufacturing of battery packs to be used in a two megawatt energy storage system ordered by the AES Corporation.
pSivida Limited, a global drug delivery company, today announced that on December 27, 2007, the Company received a letter from the NASDAQ Listing Qualifications Department notifying the Company that, for the last 30 consecutive business days, the bid price of the Company's American Depositary Shares has closed below the minimum $1.00 per share required for continued listing on the NASDAQ Global Market.
AlphaRx Inc., a leader in the development of Nanotechnology for Drug Delivery Platforms, announce that in order to meet TSX Venture Exchange listing requirements, its CEO, CFO, directors, consultants and employees plan to exercise stock options to purchase 3,300,000 shares of AlphaRx common stock.